Is Marijuana Effective Against Neuropathic Pain

Today's post is from scientistlive.com (see link below) and is yet another article about the benefits of marijuana for neuropathy patients. It's based on another small study by researchers at San Diego School of Medicine but the 'cannabis as analgesic' evidence is mounting with time. Others are also working on cannabis derivatives which don't give the high and don't require you to smoke, which could be beneficial to ex-smokers and people who aren't keen on getting stoned. An extract of cannabis has been developed into a drug for multiple sclerosis called Sativex. This is taken as a spray under the tongue. An artificial form of cannabis’ active ingredient delta 9-tetrahydrocannabinol (THC) is also licensed, as dronabinol (Marinol). These preparations do not cause the ‘high’ of the illegal drug.
*The biggest problem for neuropathy patients who wish to go down this road, is the legal one. It's then a lottery as to where you live and what the laws are but wherever that may be, let's hope that it doesn't lead to what happens in tomorrow's video post, which may put you off forever!

Marijuana effective against HIV pain 
  

In a double-blind, placebo-controlled clinical trial to assess the impact of smoked medical cannabis, or marijuana, on the neuropathic pain associated with HIV, researchers at the University of California, San Diego School of Medicine found that reported pain relief was greater with cannabis than with a placebo. The study, sponsored by the University of California Center for Medical Cannabis Research (CMCR) based at UC San Diego, will be published on line, August 6 in the journal Neuropsychopharmacology.

Led by Ronald J. Ellis, M.D., Ph.D., associate professor of neurosciences at UCSD School of Medicine, the study looked at 28 HIV patients with neuropathic pain not adequately controlled by other pain-relievers, including opiates. They took part in the controlled study as outpatients at the UCSD Medical Center. The proportion of subjects achieving pain reduction of 30 percent or more was greater for those smoking cannabis than those smoking the placebo.

"Neuropathy is a chronic and significant problem in HIV patients as there are few existing treatments that offer adequate pain management to sufferers," Ellis said. "We found that smoked cannabis was generally well-tolerated and effective when added to the patient's existing pain medication, resulting in increased pain relief."

Each trial participant participated in five study phases over seven weeks. During two five-day phases, randomly selected participants smoked either cannabis or placebo cigarettes made from whole plant material with cannabinoids (the psychoactive compound found in marijuana) removed, both provided by the National Institute on Drug Abuse. Outcome was tested by standardised tests measuring analgesia (lessened pain sensation), improvement in function and relief of pain-associated emotional distress.

Using verbal descriptors of pain magnitude, cannabis was associated with an average reduction of pain intensity from 'strong' 'to mild-to-moderate' in cannabis smokers, according to Ellis. Also, cannabis was associated with a sizeable (46% versus 18% for placebo) proportion of patients reporting clinically meaningful pain relief.

The study's findings are consistent with and extend other recent research supporting the short-term efficacy of cannabis for neuropathic pain, also sponsored by the CMCR.

"This study adds to a growing body of evidence that indicates that cannabis is effective, in the short-term at least, in the management of neuropathic pain," commented Igor Grant, M.D., professor of psychiatry and director of the CMCR.

http://www.scientistlive.com/European-Science-News/Pharmacology/Marijuana_effective_against_HIV_pain/20850/